4588.T JPX
Oncolys BioPharma Inc.
1W: -4.8%
1M: +28.6%
3M: +102.2%
YTD: +174.1%
1Y: +852.2%
3Y: +1024.1%
5Y: +267.8%
¥6,490.00 ($41.16)
+510.00 (+8.53%)
Weekly Expected Move ±14.7%
¥4216
¥5098
¥5980
¥6862
¥7744
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$4.6B
+42.4% ▲
5Y CAGR: +10.3%
Total Liabilities
$556M
+24.5% ▲
5Y CAGR: -6.9%
Shareholders Equity
$4.0B
+45.3% ▲
5Y CAGR: +14.8%
Cash & Investments
$3.7B
+54.4% ▲
5Y CAGR: +12.5%
Total Debt
$320M
-1.4% ▼
5Y CAGR: -9.4%
Net Debt
-$3.4B
-60.8% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $3.2B | $1.5B | $1.3B | $2.2B | $3.7B |
| Short-Term Investments | $245M | $245M | $245M | $245M | $47M |
| Cash & ST Investments | $3.5B | $1.7B | $1.5B | $2.4B | $3.7B |
| Net Receivables | $352M | $318M | $102M | $102M | $373M |
| Inventory | $12M | $24M | $5M | $5M | $4M |
| Other Current Assets | $24M | $506K | $12K | $46M | $12K |
| Total Current Assets | $4.2B | $2.6B | $2.0B | $3.1B | $4.5B |
| Property, Plant & Equip. | $21M | $21M | $0 | $22M | $0 |
| Goodwill & Intangibles | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $56M | $21M | $64M | $21M | $21M |
| Other Non-Current Assets | $17M | $19K | $21M | $57M | $40M |
| Total Non-Current Assets | $94M | $42M | $85M | $101M | $62M |
| Total Assets | $4.3B | $2.7B | $2.0B | $3.2B | $4.6B |
| — Liabilities — | |||||
| Accounts Payable | $106M | $61M | $193M | $0 | $0 |
| Short-Term Debt | $239M | $228M | $128M | $128M | $244M |
| Deferred Revenue | -$106M | -$61M | $0 | $0 | $110M |
| Other Current Liabilities | $219M | $131M | $224M | $42M | $102M |
| Total Current Liabilities | $430M | $322M | $379M | $252M | $471M |
| Long-Term Debt | $256M | $156M | $161M | $167M | $67M |
| Other Non-Current Liab. | $6M | $8M | $8M | $8M | $9M |
| Total Non-Current Liabilities | $268M | $170M | $188M | $194M | $85M |
| Total Liabilities | $698M | $492M | $567M | $447M | $556M |
| — Equity — | |||||
| Common Stock | $9.0B | $3.0B | $3.6B | $5.1B | $4.4B |
| Retained Earnings | -$14.5B | -$1.4B | -$3.4B | -$5.1B | -$2.1B |
| Accumulated OCI | $8M | $8M | $15M | $8M | $8M |
| Total Stockholders Equity | $3.6B | $2.2B | $1.5B | $2.8B | $4.0B |
| Total Liabilities & Equity | $4.3B | $2.7B | $2.0B | $3.2B | $4.6B |
| — Key Metrics — | |||||
| Total Debt | $503M | $394M | $315M | $325M | $320M |
| Net Debt | -$2.7B | -$1.1B | -$973M | -$1.8B | -$3.4B |
| Total Investments | $301M | $266M | $309M | $266M | $68M |